...
首页> 外文期刊>Pathology oncology research: POR >Clusterin Expression Inversely Correlates with Chemosensitivity and Predicts Poor Survival in Patients with Locally Advanced Cervical Cancer Treated with Cisplatin-Based Neoadjuvant Chemotherapy and Radical Hysterectomy
【24h】

Clusterin Expression Inversely Correlates with Chemosensitivity and Predicts Poor Survival in Patients with Locally Advanced Cervical Cancer Treated with Cisplatin-Based Neoadjuvant Chemotherapy and Radical Hysterectomy

机译:Clusterin的表达与化学敏感性呈负相关,并预测以顺铂为基础的新辅助化疗和根治性子宫切除术治疗的局部晚期宫颈癌患者的生存率较差

获取原文
           

摘要

Overexpression of clusterin, an antiapoptotic molecule, has been reported to induce resistance to chemotherapy in a variety of cancer cell types. The aim of this study was to evaluate the significance of clusterin expression to predict response to platinum-based neoadjuvant chemotherapy and survival of patients with invasive cervical cancer who subsequently underwent radical hysterectomy. Biopsy specimens of invasive cervical cancer before neoadjuvant chemotherapy were obtained from 46 patients who subsequently underwent radical hysterectomy at Hokkaido University Hospital and Gunma University Hospital from 1994 to 2007. The expression of clusterin protein was analyzed by immunohistochemistry. Findings were evaluated in relation to several clinicopathological factors. Survival analyses were performed by the Kaplan-Meier curves and the log-rank test. Independent prognostic factors were determined by multivariate Cox regression analysis. Clusterin protein was mainly present in the cytoplasm of cervical cancer cells. The expression of clusterin protein in cervical cancer tissues before neoadjuvant chemotherapy was significantly related to poor response to chemotherapy among factors analyzed. Univariate analysis on prognostic factors showed that response to chemotherapy (p?=?0.01), lymph node metastasis (p?=?0.02), and clusterin expression (p?=?0.02) were related to survival. Multivariate analysis revealed that lymph node metastasis (p?=?0.03), and clusterin expression (p?=?0.03) were independent prognostic factors for survival of cervical cancer patients. We conclude that clusterin expression could be a new molecular marker to predict response to platinum-based chemotherapy and survival of patients with cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy.
机译:据报道,簇蛋白(一种抗凋亡分子)的过度表达可诱导多种癌细胞对化学疗法的耐药性。这项研究的目的是评估簇蛋白表达的重要性,以预测对铂类新辅助化疗的反应以及随后行根治性子宫切除术的浸润性宫颈癌患者的生存率。 1994年至2007年在北海道大学医院和群马大学医院进行了根治性子宫切除术的46例患者中,获得了新辅助化疗前浸润性宫颈癌的活检标本。通过免疫组织化学分析了clusterin蛋白的表达。评估结果与几种临床病理因素有关。生存分析通过Kaplan-Meier曲线和对数秩检验进行。通过多因素Cox回归分析确定独立的预后因素。 Clusterin蛋白主要存在于宫颈癌细胞的细胞质中。在分析的新因素中,新辅助化疗前宫颈癌组织中簇蛋白的表达与化疗反应差有关。对预后因素的单因素分析表明,对化疗的反应( p ?=?0.01),淋巴结转移( p ?=? 0.02)和clusterin表达( p ?=?0.02)与生存率有关。多变量分析显示,淋巴结转移( p ?=?0.03)和簇蛋白表达( p ?== 0.03)是宫颈癌患者生存的独立预后因素。我们得出结论,簇蛋白的表达可能是新的分子标记,可以预测对基于铂类化学疗法的反应以及新辅助化学疗法和根治性子宫切除术治疗的宫颈癌患者的存活率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号